1. Recent Advances
11/21/16 David Weiner selected as Top
20 Translational Researcher by Nature
Biotechnology
11/14/16 INO-3112 generates T cell immune
responses in patients with HPV-associated
head and neck cancer
11/10/16 Zika vaccine protects animals
from infection, brain damage and death
10/24/16 FDA requests additional infor-
mation for phase III program for VGX-
3100; trial initiation delayed
10/21/16 Inovio CEO selected as 2016
Healthcare Innovator by Philadelphia
Business Journal
10/12/16 Inovio expands executive team
9/12/16 Zika vaccine selected as Popular
Mechanics’ 2016 Technology Breakthrough
8/29/16 Second human Zika vaccine trial
launches in Puerto Rico
8/16/16 Veterinary foot and mouth dis-
ease vaccine licensed to Plumbline Life
Sciences
8/11/16 Inovio expands positive phase I
Ebola vaccine trial
Inovio’s T cell activating immunotherapy
technology to make transformational step with
initiation of phase III for cervical dysplasia
and first immuno-oncology combination in
partnership with MedImmune/AstraZeneca.
Investment Highlights
Inovio in final steps to start phase III study for VGX-3100 HPV immunotherapy in
cervical pre-cancer in 1H17. Trial package submitted to FDA in September 2016. FDA
requested additional device shelf life data, may have other questions; placed program
on clinical hold prior to initiation.
• First-in-class clinically relevant efficacy achieved in controlled phase II study
of high grade cervical pre-cancer (CIN 2/3).
• Met primary endpoint for lesion regression and secondary endpoint for viral clearance.
• Phase 2b data published in The Lancet is an industry first, demonstrating the
correlation of antigen-specific CD8+ T cells (generated in the body) directly to
clinical efficacy.
• Current surgical procedure is invasive and has been associated with pre-term
births; it cannot eliminate the cancer-causing virus from untreated tissue.
Major pharma partnership with MedImmune moving toward Inovio’s first immuno-
oncology combination study by year end.
• Using Inovio’s powerful antigen-specific T cell generation with its broad portfolio
of immuno-oncology molecules, which include checkpoint inhibitors.
• Acquired exclusive rights to INO-3112 for the treatment of HPV-related cancers.
• Upfront payment of $27.5 million; paying all development costs; development
and commercial milestone payments amounting to $700 million; up to double-
digit tiered royalties on INO-3112 product sales.
• Agreement includes joint research to develop two additional DNA-based cancer
vaccine products.
Inovio’s immunotherapies are designed to treat as well as prevent diseases.
• DNA code in the immunotherapy enables the body to produce the desired target
antigen(s) relating to a cancer or infectious disease, inducing antigen-specific
preventive antibody and therapeutic T-cell immune responses most similar to the
body’s natural immune response.
• The genetic code is designed to create two strategic capabilities: break the
tolerance of the immune system to cancerous cells or generate universal
immune responses against multiple unmatched strains of a pathogen such as
influenza. The novel SynCon®
DNA sequences are patentable.
• Potential to be used as monotherapies against early stage or slowly progressing
cancers, in combination with third party immuno-oncology products, or in
combination with in-house DNA-based monoclonal antibodies (dMAb).
Best-in-class in vivo T cell activation positions technology for combination immuno-
oncology strategies.
• Checkpoint inhibitors have invigorated tremendous enthusiasm for immuno-
About the Company
NASDAQ INO
Recent market price1
$8.33
52-week range $4.50-$11.69
Shares outstanding2
74.0M
Market capitalization1
$616.4M
Avg. daily vol. (3 mo.)1
1.2M
Cash & short term investments2
$119.7M
Debt2
$0
Inovio.
Taking Immunotherapy
to the Next Level
1
November 14, 2016 2
September 30, 2016

2. oncology approaches, but their 15%-20% response rates (as monotherapies)
have led thought leaders to highlight the need for combination therapies including
technologies such as cancer vaccines. While checkpoint inhibitors are overcom-
ing cancer cells’ ability to hide from killer T cells, there must be more pre-existing
killer cells to destroy cancer cells at a higher level. Inovio’s technology has this
potential capability.
• Robust antigen-specific T cell responses correlated to efficacy in phase II
validates technology platform.
• Robust killer T cell immune responses reported in 10 evaluable patients with head
and neck cancer are a step showing Inovio’s potential to address cancers.
• hTERT DNA cancer immunotherapy, relevant to 85% of cancers, generated
robust T-cell immune responses, reduced tumors, prevented tumor recurrence,
and increased the rate of survival in preclinical studies.
DNA-based monoclonal antibody technology application introduces vast clinical
and commercial potential.
• Using the same core DNA plasmid technology, genetic code enables the body
to produce monoclonal antibodies able to provide rapid protection against
infectious disease or fight cancers with checkpoint inhibition, tumor blocking
pathways, or other cytotoxic mechanisms.
• DARPA awarded Inovio and collaborators, including MedImmune, $57M to
develop dMAb products against influenza, antibiotic resistant bacteria, and Ebola.
Targeting multiple challenging infectious diseases with unmet needs including
Ebola, MERS, Zika, HIV, and hepatitis.
About $135M in third party grants, including NIH & DARPA.
Inovio Vision 2020 highlights the company’s aspiration to have three products filed
for marketing approval with the FDA or in phase III by the year 2020 from three
development paths: HPV-related pre-cancers, cancer, and infectious diseases.
Scientific Advisory Board
David B. Weiner, Ph.D., Chairman
Executive VP & Director, Wistar
Institute Vaccine Center
Synthetic vaccine pioneer
Anthony Ford-Hutchinson, Ph.D.
Former SVP, Merck Vaccines R&D
Stanley A. Plotkin, M.D.
Emeritus Professor, Wistar & UPenn
Principal Vaxconsult
Board of Directors
Avtar Dhillon, M.D.
Chairman of the Board
Ex-MDS Healthcare
Simon X. Benito
Former SVP, Merck Vaccines
Angel Cabrera, Ph.D.
President, George Mason University
Morton Collins, Ph.D.
General Partner, Battelle Ventures
J. Joseph Kim, Ph.D.
President & CEO, Inovio
Adel Mahmoud, Ph.D.
Former President, Merck Vaccines
Professor, Dept. Molecular Biology,
Princeton University
David B. Weiner, Ph.D.
Nancy Wysenski, MBA
Former COO of Endo Pharmaceuticals
& Vertex Pharmaceuticals
Management
J. Joseph Kim, Ph.D.
President and Chief Executive Officer
Ex-Merck
Peter Kies
Chief Financial Officer
Ex-Ernst & Young
Niranjan Y. Sardesai, Ph.D.
Chief Operating Officer
Developed/commercialized products
Mark L. Bagarazzi, M.D.
Chief Medical Officer
Ex-Merck regulatory affairs, vaccines
Contact
Bernie Hertel
VP Investor Relations & Communications
Inovio Pharmaceuticals
858 410 3101
bhertel@inovio.com • www.inovio.com
This Corporate Profile contains certain forward-looking statements relating to our business, including our plans to develop DNA vaccines and electroporation-based drug and gene delivery
technologies.Actual events or results may differ from the expectations set forth herein as a result of a number of factors,including uncertainties inherent in pre-clinical studies,clinical trials and
product development programs,including,but not limited to,the fact that pre-clinical and clinical results referenced in this profile may not be indicative of results achievable in other trials or for
other indications, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative
of results achievable in human studies, our ability to obtain necessary regulatory approvals, capital market conditions and other factors set forth in our Annual Report on Form 10-K for the year
ended December 31, 2015, our Form 10-Q for the quarter ended September 30, 2016, and other regulatory filings from time to time.
Product Milestones
Internally Funded Externally Funded
Indication Pre-clinical Phase I Phase II Milestone
1H17
Initiate phase III
1Q17
Start IO combo study
2016
Report interim data
1Q17
Start PI/II
2H17
Report phase I study data
2016
Study initiated with NCI
2017
Report data
2016
Publish clinical data in
peer-reviewed journal
2016
Report phase I study data
2017
Report P1 data with possible
efficacy signals
Cervical Dysplasia Therapeutic
HPV-Related Cancers Therapeutic
Prostate Cancer Therapeutic
hTERT (antigen) Therapeutic
Hepatitis B Therapeutic
Hepatitis C Therapeutic
HIV Preventive/Therapeutic
Ebola Preventive
MERS Preventive
Zika Preventive